On-demand webinar: Screening for and managing early type 1 diabetes
As screening initiatives are being set up internationally, and with the availability of clinical coding for presymptomatic type 1 diabetes (T1D), an increasing number of people are being identified with T1D before they need insulin treatment. These people need careful support and care and it falls on us in secondary care to provide this. This session will outline the different screening initiatives around the UK, the approaches to managing early T1D and review some case histories.
The learning outcomes are:
- Presymptomatic type 1 diabetes can be detected a number of years before the onset of symptoms
- Early detection of T1D has advantages
- Screen detected T1D has a milder clinical presentation and lower insulin requirements and requires a personalised insulin regimen
This webinar has been instigated and organised by ABCD. The support from our corporate sponsors has allowed us to provide this valuable educational meeting free of charge to all delegates. Sponsors have had no input into the agenda or the selection of speakers.
Speakers
-
Professor Mark Evans
Honorary Consultant Physician
Mark is a Consultant Physician working in diabetes and general medicine in Cambridge University Hospitals (Addenbrookes) and a Clinical Scientist based in the University of Cambridge’s Wellcome-MRC Institute of Metabolic Science (www.ims.cam.ac.uk). He trained in Medicine in London, including time spent as a research fellow at Kings College Hospital in London and then at Yale University in USA. He moved to Cambridge in 2002 to set up his own research team. His clinical and academic interests are in hypoglycaemia, type 1 diabetes, immunotherapy, medical technology and structured education for diabetes. -
Professor Parth Narendran
Professor of Diabetes Medicine
Parth's research interest focusses on understanding the autoimmune destruction of insulin secreting beta cells that lead to type 1 diabetes and exploring how this process can be modulated. He is part of a national effort to explore the feasibility and acceptability of early surveillance programmes for pre-type 1 diabetes and is also exploring which therapies are best tested in the prevention arena.
He leads the T1D clinical service at the QE Hospital in Birmingham, supporting the islet and pancreas transplant, DAFNE, transition and exercise services.
